Deutsch
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
heparin/adipositas
Der Link wird in der Zwischenablage gespeichert
Seite 1 von 810 Ergebnisse
Identifying optimal heparin management during cardiopulmonary bypass in obese patients: A prospective observational comparative study.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
The heparin regimen providing anticoagulation during cardiopulmonary bypass (CPB) is usually adapted to total body weight (TBW), but may be inaccurate in obese patients in whom TBW exceeds their ideal body weight.
OBJECTIVE
The objective is to compare the effects of heparin injection
Adjusted calculation model of heparin management during cardiopulmonary bypass in obese patients: A randomised controlled trial.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
Anticoagulation during cardiopulmonary bypass (CPB) is usually adapted to total body weight (TBW). This may be inaccurate in obese patients and lead to heparin overdose with a risk of bleeding.
OBJECTIVE
To validate the efficacy and safety of an adjusted calculation model of heparin
Twelve-week jogging training increases pre-heparin serum lipoprotein lipase concentrations in overweight/obese middle-aged men.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
OBJECTIVE
Enhancement of lipoprotein lipase (LPL) activity through drug administration has been shown to increase pre-heparin serum LPL concentrations; however, pre-heparin serum LPL responses to exercise training have not been determined. The present study was undertaken to investigate the effects
Use of subcutaneous lepirudin in an obese surgical intensive care unit patient with heparin resistance.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
OBJECTIVE
To report the use of subcutaneous lepirudin in an obese patient with heparin resistance.
METHODS
A 34-year-old morbidly obese male (weight 145 kg) presented with hypoxia on postoperative day 1 following a sigmoid colectomy. A continuous unfractionated heparin infusion was started for a
Unfractionated heparin dosing in obese patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Background The effect of obesity on the pharmacokinetics and pharmacodynamics of unfractionated heparin is not clearly understood, therefore to reduce the risk of bleeding, maximal dose (capped) nomograms are often used. This can lead to inadequate anticoagulation and increased mortality and
Safety and efficacy of high-dose unfractionated heparin versus high-dose enoxaparin for venous thromboembolism prevention in morbidly obese hospitalized patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
High dose subcutaneous unfractionated heparin for prevention of venous thromboembolism in overweight neurocritical care patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
Timing and dosing of chemical venous thromboembolism (VTE) prophylaxis in brain injury is controversial. Risk of bleeding while using high dose unfractionated heparin (UFH) in overweight patients to prevent VTE is also unknown. The purpose of this study was to describe the use of subcutaneous
Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
To determine the safety and efficacy of high-dose subcutaneous unfractionated heparin (UFH) for prevention of venous thromboembolism (VTE) in overweight and obese patients.
Single-center retrospective observational cohort study.
Large academic tertiary care medical center.
A total of 1335 adults who
Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
A 32-year-old, morbidly obese African-American woman developed bilateral pulmonary emboli 12 days after undergoing Roux-en-Y gastric bypass surgery. Three days later, after receiving heparin and warfarin, she developed heparin-induced thrombocytopenia type II (HIT-II). An argatroban
The effect of a heparin analogue, ITF-5005, on diabetes incidence and insulitis in the non-obese diabetic mouse.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
It has been suggested that heparin and its analogues may have a suppressive effect on the immune response by interfering with T-lymphocyte heparinase activity, thus altering the ability of T-lymphocytes to penetrate the extracellular matrix and migrate to target tissues. We have investigated whether
Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
Most literature available for unfractionated heparin (UFH) supports the use of actual body weight for dosing all patients, yet a small proportion of the patients in these studies were morbidly obese. The most appropriate dosing strategy for therapeutic UFH in this patient population is
Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
Obesity is endemic in the United States and obese patients are at increased risk of thromboembolism but little data are available for dosing unfractionated heparin (UFH). We evaluated the relationship between obesity and UFH efficacy during critical illness by examining UFH infusions in
Evaluation of an Unfractionated Heparin Pharmacy Dosing Protocol for the Treatment of Venous Thromboembolism in Nonobese, Obese, and Severely Obese Patients.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
Despite large interpatient variability in dose response, heparin is utilized for treatment of venous thromboembolism (VTE). Current data on the optimal heparin dosing in obese patients are conflicting.
OBJECTIVE
The objective was to evaluate the time and dose required to achieve a
Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
BACKGROUND
Confusion exists when dosing heparin using a weight-based nomogram in the obese population. At 2 affiliated community teaching hospitals, we compared the activated partial thromboplastin time (aPTT) values in morbidly obese and nonmorbidly obese patients using a standardized nomogram and
Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels.
Nur registrierte Benutzer können Artikel übersetzen
Einloggen Anmelden
There is limited guidance on intravenous dosing of unfractionated heparin in obese patients. The purpose of this study was to determine the efficacy and safety of a standard unfractionated heparin (UFH) protocol in obese patients based on total body weight (TBW) or adjusted body weight (ABW) to
Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird
- Arbeitet in 55 Sprachen
- Von der Wissenschaft unterstützte Kräuterkuren
- Kräutererkennung durch Bild
- Interaktive GPS-Karte - Kräuter vor Ort markieren (in Kürze)
- Lesen Sie wissenschaftliche Veröffentlichungen zu Ihrer Suche
- Suchen Sie nach Heilkräutern nach ihrer Wirkung
- Organisieren Sie Ihre Interessen und bleiben Sie über Neuigkeiten, klinische Studien und Patente auf dem Laufenden
Geben Sie ein Symptom oder eine Krankheit ein und lesen Sie über Kräuter, die helfen könnten, geben Sie ein Kraut ein und sehen Sie Krankheiten und Symptome, gegen die es angewendet wird.
* Alle Informationen basieren auf veröffentlichten wissenschaftlichen Forschungsergebnissen
